Bernard Combe1, Frank Behrens2, Neil McHugh2, Fiona Brock2, Urs Kerkmann2, Blerina Kola2, Gaia Gallo2. 1. From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy.B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. b-combe@chu-montpellier.fr. 2. From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy.B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe.
Abstract
OBJECTIVE: To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA). METHODS: Data from patients with PsA who received ETN alone (n = 322) or combined withmethotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies. RESULTS: Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire-Disability Index improvement. CONCLUSION:ETN with and without MTX provided similar benefits in active PsA.
RCT Entities:
OBJECTIVE: To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA). METHODS: Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies. RESULTS: Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire-Disability Index improvement. CONCLUSION: ETN with and without MTX provided similar benefits in active PsA.
Authors: Gustavo Deza; Jaime Notario; Marta Ferran; Emma Beltrán; Miriam Almirall; Rebeca Alcalá; José Carlos Ruiz-Carrascosa; Ricardo Sánchez; Silvia Pérez; María Luz García-Vivar; Eva Galíndez; Maribel Mora; Jesús Rodríguez; Fernando Gallardo Journal: Rheumatol Int Date: 2018-08-24 Impact factor: 2.631
Authors: Jasvinder A Singh; Gordon Guyatt; Alexis Ogdie; Dafna D Gladman; Chad Deal; Atul Deodhar; Maureen Dubreuil; Jonathan Dunham; M Elaine Husni; Sarah Kenny; Jennifer Kwan-Morley; Janice Lin; Paula Marchetta; Philip J Mease; Joseph F Merola; Julie Miner; Christopher T Ritchlin; Bernadette Siaton; Benjamin J Smith; Abby S Van Voorhees; Anna Helena Jonsson; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Laura C Coates; Alice Gottlieb; Marina Magrey; W Benjamin Nowell; Ana-Maria Orbai; Soumya M Reddy; Jose U Scher; Evan Siegel; Michael Siegel; Jessica A Walsh; Amy S Turner; James Reston Journal: Arthritis Rheumatol Date: 2018-11-30 Impact factor: 10.995
Authors: Jasvinder A Singh; Gordon Guyatt; Alexis Ogdie; Dafna D Gladman; Chad Deal; Atul Deodhar; Maureen Dubreuil; Jonathan Dunham; M Elaine Husni; Sarah Kenny; Jennifer Kwan-Morley; Janice Lin; Paula Marchetta; Philip J Mease; Joseph F Merola; Julie Miner; Christopher T Ritchlin; Bernadette Siaton; Benjamin J Smith; Abby S Van Voorhees; Anna Helena Jonsson; Amit Aakash Shah; Nancy Sullivan; Marat Turgunbaev; Laura C Coates; Alice Gottlieb; Marina Magrey; W Benjamin Nowell; Ana-Maria Orbai; Soumya M Reddy; Jose U Scher; Evan Siegel; Michael Siegel; Jessica A Walsh; Amy S Turner; James Reston Journal: Arthritis Care Res (Hoboken) Date: 2018-11-30 Impact factor: 4.794
Authors: Rubén Queiro; Juan D Cañete; Carlos Montilla; Miguel Abad; María Montoro; Susana Gómez; Ana Cábez Journal: Arthritis Res Ther Date: 2017-03-29 Impact factor: 5.156
Authors: Bernard Combe; Tsen-Fang Tsai; J Eugene Huffstutter; Aubrey Trevelin Sprabery; Chen-Yen Lin; So Young Park; Andris Kronbergs; Matthew M Hufford; Peter Nash Journal: Arthritis Res Ther Date: 2021-01-27 Impact factor: 5.156